Price T Rowe Associates Inc Kymera Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,390,658 shares of KYMR stock, worth $314 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
6,390,658
Previous 6,332,012
0.93%
Holding current value
$314 Million
Previous $255 Million
25.06%
% of portfolio
0.02%
Previous 0.03%
Shares
15 transactions
Others Institutions Holding KYMR
# of Institutions
163Shares Held
63.1MCall Options Held
22.6KPut Options Held
14.4K-
Baker Bros. Advisors LP New York, NY6MShares$294 Million2.38% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.35MShares$263 Million21.28% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$253 Million4.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$237 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.31MShares$212 Million0.02% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.68B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...